IDT Opens SGD 6 Million Manufacturing Facility in Singapore
News Jul 24, 2013
In January of 2012, IDT acquired the oligo business of Singapore’s top supplier, 1st BASE Pte. Ltd. Shortly thereafter, IDT began work to create a state-of-the art hub for oligo manufacturing and support dedicated to the Asian market. IDT completed the nearly SGD 6 million project in spring of 2013, and the Singapore company’s synthesis and other processes are now fully integrated with IDT’s operations in the US and Europe.
IDT’s investment in Singapore means that researchers throughout the region can now enjoy quicker delivery of the same high quality custom nucleic acid products they expect from IDT. Through its Asian network of highly skilled sales professionals and 21 appointed distributors, IDT now serves Malaysia, Indonesia, Thailand, Taiwan, the Philippines, Vietnam, Bangladesh, Hong Kong, Nepal, Sri Lanka, and Myanmar from its Singapore company. In the coming months, IDT will expand the services it offers from Singapore to include all the Asia Pacific region’s major markets.
“Our new synthesis and support capabilities in Singapore increase the speed with which we can deliver IDT products to our customers in Asia by 2-3 days,” noted Trey Martin, Chief Operating Officer at IDT. “Scientists can move forward with their research that much more quickly, which will add to the value IDT already contributes to their important work.”
Said Dr Joseph A. Walder, Founder and CEO of IDT, “For several years, we’ve looked forward to the day that we could bring to Asia what has made IDT so successful in North America and Europe – the highest quality custom biology products, delivered quickly, at prices that enable new and more research. Our team in Asia now has a world class facility in Singapore, with the support of IDT’s global infrastructure backing it up. We’re proud today to offer its benefits to the scientific community in Asia.”
“We strongly welcome IDT’s decision to set up a new oligonucleotide manufacturing facility that supports the scientific community in Singapore and the extended Asia Pacific region. Oligonucleotide manufacturing is knowledge-intensive, and requires a high proportion of skilled degree and diploma holders. This new investment will create excellent job opportunities for Singaporeans,” said Mr Kevin Lai, Director, Biomedical Sciences, Singapore Economic Development Board.
To celebrate, IDT will host an opening ceremony on Wednesday, 24 July from 4 pm to 6 pm. The event will include facility tours, networking, and presentations by IDT’s leadership. The presentations will highlight IDT’s latest innovations in support of synthetic biology, next generation sequencing, and quantitative PCR applications.
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.